Companies · Biotechnology

Cleveland Diagnostics, Inc.

CLEVELAND · Biotechnology

Diligence memoA one-page analyst read on Cleveland Diagnostics, Inc. — recommendation, valuation, rhythm, risks.
$73.3M
Total raised · real
4
Rounds
0.3×
Latest step-up
Top 14%
Sector rank · raised
Series C
Latest stage · inferred · Tue Oct 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Cleveland Diagnostics, Inc. looks under-valued against its niche peers and is active on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.41× the median modeled value of Series C Biotechnology companies in 2025–2027 (58 peers) — value vs value, same stage and era.
Active
  • Last raise 9 mo ago; this sector typically re-raises about every 14 months.
  • Raising on or ahead of the sector's normal rhythm.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Cleveland Diagnostics, Inc. is one of 4291 Biotechnology companies tracked from CLEVELAND. By capital raised it ranks in the upper tier (ahead of 87% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

medical-devices

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
7
Investors (latest)
2025-10-07
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$250M$500M$750M$1.0BSeed · 2015-03-03 Raised $2.0M (real) Modeled valuation $88M (est)$2.0M$88MSeed2015Seed · 2016-11-16 Raised $440K (real) Modeled valuation $20M (est)$440K$20MSeed2016Series C · 2024-01-16 Raised $56M (real) Modeled valuation $599M (est)$56M$599MSeries C2024Series C · 2025-10-07 Raised $14M (real) Modeled valuation $79M (est)$14M$79MSeries C2025+$440K+$56M+$14MCumulative $73M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$2.0M · 2015
Seed extension$440K · 2016
Series C$56.5M · 2024no Series A / Series B on file
Series C extension$14.4M · 2025

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Series A, Series B — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 40%.

Modeled valuation trajectory
$79.3M
Base estimate est.
$44.6M
Conservative case
$101.1M
Upside case
$96.1M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ca $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Seed · modeled $87.9M · 2015-03-032015Seed · modeled $19.6M · 2016-11-16Series C · modeled $599.3M · 2024-01-16Series C · modeled $79.3M · 2025-10-072025
Model inputs · modeled:benchmark-stage-stepup-v1
15%
Dilution assumption
Implied ownership sold in the financing.
62%
Survival probability
46% low · 72% high
1.46×/yr
Annual markup
1.68×/yr upside case
0.7 yr
Elapsed time used
0.7 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
42 mo
Avg between rounds
$6.9M/yr
Capital velocity
11.3 yr
On record since
2015
First round
4
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 10× above median
This company$73.3M
Sector median$7.2M
Latest round — vs other Series C rounds in sector (real $, this stage) 0.3× of median
This company$14.4M
Sector median$46.5M
Modeled value — vs sector median (estimate, all stages) 1.2× above median
This company$79.3M
Sector median$64.2M

Raised more than 87% of sector peers (real $). Modeled value above 54% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #42 of 58.

This companyCohort peer
$10.0M$100.0M$1.0B$10.0M$100.0M$1.0BCapital raised (log)Newleos Therapeutics, Inc. · Series C Raised $93.4M · modeled $659.2M (est)Biolinq Inc · Series C Raised $247.4M · modeled $618.5M (est)Atsena Therapeutics, Inc. · Series C Raised $146.0M · modeled $605.7M (est)Galvanize Therapeutics, Inc. · Series C Raised $150.7M · modeled $581.7M (est)X4 Pharmaceuticals, Inc · Series C Raised $320.3M · modeled $494.8M (est)Endless Corp · Series C Raised $79.0M · modeled $493.8M (est)Ikena Oncology, Inc. · Series C Raised $117.6M · modeled $448.6M (est)Imbria Pharmaceuticals, Inc. · Series C Raised $140.2M · modeled $405.5M (est)Bambusa Therapeutics, Inc. · Series C Raised $67.4M · modeled $375.0M (est)Plexium, Inc. · Series C Raised $60.1M · modeled $361.1M (est)Latigo Biotherapeutics, Inc. · Series C Raised $50.0M · modeled $357.5M (est)Neuros Medical, Inc. · Series C Raised $160.0M · modeled $338.1M (est)Cleveland Diagnostics, Inc. (this company) Raised $73.3M · modeled $79.3M (est)Cleveland Diagnostics, Inc.
CompanyStageRaised · realValue · estvs peer med.
Newleos Therapeutics, Inc.Series C$93.4M$659.2M3.43×
Biolinq IncSeries C$247.4M$618.5M3.22×
Atsena Therapeutics, Inc.Series C$146.0M$605.7M3.15×
Galvanize Therapeutics, Inc.Series C$150.7M$581.7M3.03×
X4 Pharmaceuticals, IncSeries C$320.3M$494.8M2.57×
Endless CorpSeries C$79.0M$493.8M2.57×
Ikena Oncology, Inc.Series C$117.6M$448.6M2.33×
Imbria Pharmaceuticals, Inc.Series C$140.2M$405.5M2.11×
Bambusa Therapeutics, Inc.Series C$67.4M$375.0M1.95×
Plexium, Inc.Series C$60.1M$361.1M1.88×
Latigo Biotherapeutics, Inc.Series C$50.0M$357.5M1.86×
Neuros Medical, Inc.Series C$160.0M$338.1M1.76×
Cleveland Diagnostics, Inc. this companySeries C$73.3M$79.3M0.41×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$2.0M2015-03-03$9.9M$87.9M85%
Seed$440K2016-11-16$2.2M$19.6M90%
Series C$56.5M2024-01-16$376.6M$599.3M90%
Series C$14.4M2025-10-07$96.1M$79.3M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$2.0M2015-03-03
    • First recorded raise — entered as Seed.
    • 8 investors on this round.
  2. Seed$440K2016-11-16
    • Raised 20 mo later, in step with the ~14 mo sector norm.
    • Round 4.5× smaller than the prior — bridge or down round.
    • 5 investors on this round.
  3. Series C$56.5M2024-01-16
    • Raised again after 86 mo — slower than the ~14 mo sector norm.
    • Round 128.3× larger than the prior — scaling up.
    • 26 investors on this round.
  4. Series C$14.4M2025-10-07
    • Raised again after 21 mo — slower than the ~14 mo sector norm.
    • Round 3.9× smaller than the prior — bridge or down round.
    • 7 investors on this round.
Intelligence
2029 ~Q2
Modeled next raise · ~42mo cadence
$14.4M
Modeled next size est.range $14.4M$23.1M
0.3×
Last step-up
$6.9M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Ben Bronstein3 other2015-03
ANDREW SUMMERS2 other2025-10
Jeffrey Marshall2 other2015-03
Karen Shanahan2 other2015-03
Arnon Chait1 other2015-03
JOSEPH RICH1 other2016-11
NOEL JEE1 other2025-10
SAMEER ROHATGI1 other2024-01
DARA WRIGHT2025-10
Ilan Goldstein2015-03
Levi Kushnir2015-03
Tim Longville2016-11
Registry & provenance

Cleveland Diagnostics, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1637038
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Centerline Biomedical, Inc.BiotechnologySeries B$71.8M$55.0Mnetwork1 shared operator · same sector
Redona Therapeutics, Inc.BiotechnologySeries C$66.8M$76.1Msame sector · same stage
Apexigen, Inc.BiotechnologySeries C$66.4M$85.5Msame sector · same stage
Elicio Therapeutics, Inc.BiotechnologySeries B$105.3M$392.4Mnetwork1 shared operator · same sector
Catalyst Biosciences IncBiotechnologySeries C$65.3M$77.4Msame sector · same stage
Gradalis, Inc.BiotechnologySeries C$56.7M$79.6Msame sector · same stage
Chemomab Therapeutics Ltd.BiotechnologySeries C$55.4M$86.5Msame sector · same stage
OncoNano Medicine, Inc.BiotechnologySeries C$115.0M$84.1Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
TAI Diagnostics, Inc.BiotechnologySeries A$463.8M92%
Co-Diagnostics, Inc.BiotechnologySeries C$1.1B88%
Integrated Diagnostics, Inc.BiotechnologySeries B$242.1M88%
Gregor Diagnostics, Inc.BiotechnologySeries A$677K88%
NAT Diagnostics, Inc.BiotechnologySeed$66.6M87%
Biomark Diagnostics Inc.BiotechnologySeed$8.0M87%
Torpedo Diagnostics, Inc.BiotechnologySeed$88.8M87%
Gamma Diagnostics, Inc.BiotechnologyPre-Seed$3.7M87%
Frequently asked
How much funding has Cleveland Diagnostics, Inc. raised?
Cleveland Diagnostics, Inc. has raised approximately $73.3M in disclosed capital across 4 recorded financing rounds, aggregated from public filings.
What is Cleveland Diagnostics, Inc.'s estimated valuation?
Provath's modeled valuation for Cleveland Diagnostics, Inc. is approximately $79.3M (modeled range $44.6M–$101.1M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Cleveland Diagnostics, Inc. at?
Cleveland Diagnostics, Inc.'s latest modeled financing stage is Series C. Its most recent recorded round closed around Tue Oct 07.
What does Cleveland Diagnostics, Inc. do and where is it based?
Cleveland Diagnostics, Inc. operates in the Biotechnology sector, based in CLEVELAND.
Explore related

See where Cleveland Diagnostics, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Cleveland Diagnostics, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.